Veracyte: Sustainable Rally Supported By Spectacular Execution In Q3

Nov. 05, 2022 7:43 AM ETVeracyte, Inc. (VCYT)CDNA, NSTG, NTRA, NVTA, UNH1 Comment
Bashar Issa profile picture
Bashar Issa
3.41K Followers

Summary

  • VCYT exceeded investors' expectations, coupling solid revenue growth with improved profitability.
  • Unique international exposure offers revenue tailwinds as Europe accelerates gene diagnostic testing adoption.
  • In view of the probability that the political and regulatory pattern of 2014-2016 for LDT oversight may repeat, I am revising my regulatory risk rating from high to medium.

Scientist in the lab using microscope

Luis Alvarez/DigitalVision via Getty Images

Investment Thesis

In past articles, I talked about a paradigm shift in the gene testing industry from a "growth at all cost" to a "profitable growth" market approach pushed primarily by rising capital costs as the era of free money

This article was written by

Bashar Issa profile picture
3.41K Followers
Bashar is a contributing writer at Seeking Alpha, focusing on Long/Short investment ideas, with a geographic focus in North America. Before that, Bashar worked at an Investment Fund in the United Kingdom. He has a Master's degree in Finance from the Queen Mary University of London and a Bachelor's degree in Economics from Middlesex University.

Disclosure: I/we have a beneficial long position in the shares of NTRA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.